Global Antisense and RNAi Therapeutics Market By Technology (RNA Interference and Antisense RNA), By Application (Genetic Disease, Cancer, Skin Disorders, Respiratory Disorders, Ocular Disorders, Neurodegenerative Disorders, Infectious Disease, and Cardiometabolic & Renal Disorders), By Route of Administration (Intravenous Injections, Subcutaneous Injections, Intrathecal Injections, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Table of Contents

• 1. Executive Summary
  • 1.1. Definition
  • 1.2. Market Snapshot
  • 1.3. Market Overview
  • 1.4. Segment Overview
  • 1.5. Regional Overview
  • 1.6. Competitive Landscape
  • 1.7. Taxonomy
• 2. Global Market Overview
  • 2.1. Global Market Insights and Industry Overview
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunities
    • 2.2.4. Key Antisense and RNAi Therapeutics Market Trends
  • 2.3. Regulatory Framework
  • 2.4. Opportunity Map Analysis
  • 2.5. Opportunity Orbits
  • 2.6. PESTLE Analysis
  • 2.7. PORTER’S Five Force Analysis
  • 2.8. Drivers & Restraints Impact Analysis
  • 2.9. Value Chain Analysis
    • 2.9.1. List of Raw Materials Suppliers
    • 2.9.2. List of Antisense and RNAi Therapeutics Manufacturers
    • 2.9.3. List of Dealer/Distributors
  • 2.10. Regional Market Share and BPS Analysis
  • 2.11. Impact of Macro-economic Factors/Geopolitical Factors
• 3. Global Antisense and RNAi Therapeutics Market Analysis and Forecast, By Segment, 2020-2034
  • 3.1. Key Findings
  • 3.2. Global Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 3.3. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
    • 3.3.1. Antisense RNA
      • 3.3.1.1. Insights
      • 3.3.1.2. Key Takeaways
    • 3.3.2. RNA Interference
      • 3.3.2.1. Insights
      • 3.3.2.2. Key Takeaways
  • 3.4. Global Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 3.5. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
    • 3.5.1. Neurodegenerative Disorders
      • 3.5.1.1. Insights
      • 3.5.1.2. Key Takeaways
    • 3.5.2. Genetic Disease
      • 3.5.2.1. Insights
      • 3.5.2.2. Key Takeaways
    • 3.5.3. Cancer
      • 3.5.3.1. Insights
      • 3.5.3.2. Key Takeaways
    • 3.5.4. Skin Disorders
      • 3.5.4.1. Insights
      • 3.5.4.2. Key Takeaways
    • 3.5.5. Respiratory Disorders
      • 3.5.5.1. Insights
      • 3.5.5.2. Key Takeaways
    • 3.5.6. Ocular Disorders
      • 3.5.6.1. Insights
      • 3.5.6.2. Key Takeaways
    • 3.5.7. Infectious Disease
      • 3.5.7.1. Insights
      • 3.5.7.2. Key Takeaways
    • 3.5.8. Cardiometabolic & Renal Disorders
      • 3.5.8.1. Insights
      • 3.5.8.2. Key Takeaways
  • 3.6. Global Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 3.7. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
    • 3.7.1. Intrathecal Injections
      • 3.7.1.1. Insights
      • 3.7.1.2. Key Takeaways
    • 3.7.2. Intravenous Injections
      • 3.7.2.1. Insights
      • 3.7.2.2. Key Takeaways
    • 3.7.3. Subcutaneous Injections
      • 3.7.3.1. Insights
      • 3.7.3.2. Key Takeaways
    • 3.7.4. Others
      • 3.7.4.1. Insights
      • 3.7.4.2. Key Takeaways
• 4. Global Antisense and RNAi Therapeutics Market Analysis and Forecast, By Region, 2020-2034
  • 4.1. Key Findings
  • 4.2. Global Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    • 4.2.1. North America
      • 4.2.1.1. Regional Insights
    • 4.2.2. Europe
      • 4.2.2.1. Regional Insights
    • 4.2.3. Asia Pacific
      • 4.2.3.1. Regional Insights
    • 4.2.4. Latin America
      • 4.2.4.1. Regional Insights
    • 4.2.5. Middle East & Africa
      • 4.2.5.1. Regional Insights
  • 4.3. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Region
• 5. North America Antisense and RNAi Therapeutics Market Analysis and Forecast, 2020-2034
  • 5.1. Key Findings
  • 5.2. North America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 5.3. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
  • 5.4. North America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 5.5. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
  • 5.6. North America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 5.7. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
  • 5.8. North America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 5.9. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
    • 5.9.1. The US
    • 5.9.2. Canada
• 6. Europe Antisense and RNAi Therapeutics Market Analysis and Forecast, 2020-2034
  • 6.1. Key Findings
  • 6.2. Europe Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 6.3. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
  • 6.4. Europe Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 6.5. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
  • 6.6. Europe Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 6.7. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
  • 6.8. Europe Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 6.9. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
    • 6.9.1. Germany
    • 6.9.2. The UK
    • 6.9.3. France
    • 6.9.4. Spain
    • 6.9.5. Italy
    • 6.9.6. Russia
    • 6.9.7. Netherland
    • 6.9.8. Rest of Europe
• 7. Asia Pacific Antisense and RNAi Therapeutics Market Analysis and Forecast, 2020-2034
  • 7.1. Key Findings
  • 7.2. Asia Pacific Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 7.3. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
  • 7.4. Asia Pacific Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 7.5. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
  • 7.6. Asia Pacific Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 7.7. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
  • 7.8. Asia Pacific Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 7.9. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
    • 7.9.1. China
    • 7.9.2. Japan
    • 7.9.3. South Korea
    • 7.9.4. India
    • 7.9.5. Australia
    • 7.9.6. New Zealand
    • 7.9.7. Singapore
    • 7.9.8. Thailand
    • 7.9.9. Vietnam
    • 7.9.10. Rest of Asia Pacific
• 8. Latin America Antisense and RNAi Therapeutics Market Analysis and Forecast, 2020-2034
  • 8.1. Key Findings
  • 8.2. Latin America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 8.3. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
  • 8.4. Latin America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 8.5. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
  • 8.6. Latin America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 8.7. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
  • 8.8. Latin America Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 8.9. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
    • 8.9.1. Brazil
    • 8.9.2. Mexico
    • 8.9.3. Rest of Latin America
• 9. Middle East & Africa Antisense and RNAi Therapeutics Market Analysis and Forecast, 2020-2034
  • 9.1. Key Findings
  • 9.2. Middle East & Africa Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Technology, 2020-2034
  • 9.3. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
  • 9.4. Middle East & Africa Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
  • 9.5. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
  • 9.6. Middle East & Africa Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 9.7. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
  • 9.8. Middle East & Africa Antisense and RNAi Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 9.9. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
    • 9.9.1. South Africa
    • 9.9.2. Saudi Arabia
    • 9.9.3. UAE
    • 9.9.4. Rest of Middle East & Africa
• 10. Competitive Landscape & Company Profiles
  • 10.1. Market Competition Scenario Analysis, By Company
    • 10.1.1. Key Takeaways
  • 10.2. Overview of Major Market Players
  • 10.3. Competitor Landscape
  • 10.4. Strategic Mapping
  • 10.5. Company Life Cycle Analysis
  • 10.6. Company Market Share Analysis
  • 10.7. Company Profiles
    • 10.7.1. Sirnaomics Ltd
      • 10.7.1.1. Company Details
      • 10.7.1.2. Business Overview
      • 10.7.1.3. Product Portfolio
      • 10.7.1.4. Financial Insights
      • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.1.6. SWOT Analysis
      • 10.7.1.7. Geographic Footprint
    • 10.7.2. Silence Therapeutics
      • 10.7.2.1. Company Details
      • 10.7.2.2. Business Overview
      • 10.7.2.3. Product Portfolio
      • 10.7.2.4. Financial Insights
      • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.2.6. SWOT Analysis
      • 10.7.2.7. Geographic Footprint
    • 10.7.3. Sarepta Therapeutics
      • 10.7.3.1. Company Details
      • 10.7.3.2. Business Overview
      • 10.7.3.3. Product Portfolio
      • 10.7.3.4. Financial Insights
      • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.3.6. SWOT Analysis
      • 10.7.3.7. Geographic Footprint
    • 10.7.4. Sanofi
      • 10.7.4.1. Company Details
      • 10.7.4.2. Business Overview
      • 10.7.4.3. Product Portfolio
      • 10.7.4.4. Financial Insights
      • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.4.6. SWOT Analysis
      • 10.7.4.7. Geographic Footprint
    • 10.7.5. Ionis Pharmaceuticals, Inc
      • 10.7.5.1. Company Details
      • 10.7.5.2. Business Overview
      • 10.7.5.3. Product Portfolio
      • 10.7.5.4. Financial Insights
      • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.5.6. SWOT Analysis
      • 10.7.5.7. Geographic Footprint
    • 10.7.6. GSK plc
      • 10.7.6.1. Company Details
      • 10.7.6.2. Business Overview
      • 10.7.6.3. Product Portfolio
      • 10.7.6.4. Financial Insights
      • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.6.6. SWOT Analysis
      • 10.7.6.7. Geographic Footprint
    • 10.7.7. Arbutus Biopharma
      • 10.7.7.1. Company Details
      • 10.7.7.2. Business Overview
      • 10.7.7.3. Product Portfolio
      • 10.7.7.4. Financial Insights
      • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.7.6. SWOT Analysis
      • 10.7.7.7. Geographic Footprint
    • 10.7.8. Alnylam Pharmaceuticals, Inc
      • 10.7.8.1. Company Details
      • 10.7.8.2. Business Overview
      • 10.7.8.3. Product Portfolio
      • 10.7.8.4. Financial Insights
      • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.8.6. SWOT Analysis
      • 10.7.8.7. Geographic Footprint
• 11. Methodology and Data Source
  • 11.1. Methodology/Research Approach
  • 11.2. Market Size Estimation
  • 11.3. Market Breakdown and Data Triangulation
  • 11.4. Data Source
  • 11.5. Secondary Sources
  • 11.6. Primary Sources
  • 11.7. Appendix
  • 11.8. Disclaimer

List of Tables

• Table 1. Global Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 2. Global Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 3. Global Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 4. Global Antisense and RNAi Therapeutics Market Value (US$ Mn), By Region, 2020-2034
• Table 5. North America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 6. North America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 7. North America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 8. North America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Country, 2020-2034
• Table 9. The US Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 10. The US Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 11. The US Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 12. Canada Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 13. Canada Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 14. Canada Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 15. Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 16. Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 17. Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 18. Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Country, 2020-2034
• Table 19. Germany Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 20. Germany Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 21. Germany Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 22. The UK Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 23. The UK Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 24. The UK Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 25. France Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 26. France Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 27. France Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 28. Spain Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 29. Spain Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 30. Spain Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 31. Italy Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 32. Italy Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 33. Italy Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 34. Russia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 35. Russia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 36. Russia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 37. Netherland Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 38. Netherland Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 39. Netherland Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 40. Rest of Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 41. Rest of Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 42. Rest of Europe Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 43. Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 44. Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 45. Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 46. Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Country, 2020-2034
• Table 47. China Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 48. China Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 49. China Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 50. India Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 51. India Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 52. India Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 53. Japan Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 54. Japan Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 55. Japan Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 56. South Korea Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 57. South Korea Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 58. South Korea Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 59. Australia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 60. Australia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 61. Australia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 62. New Zealand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 63. New Zealand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 64. New Zealand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 65. Singapore Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 66. Singapore Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 67. Singapore Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 68. Thailand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 69. Thailand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 70. Thailand Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 71. Vietnam Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 72. Vietnam Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 73. Vietnam Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 74. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 75. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 76. Rest of Asia Pacific Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 77. Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 78. Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 79. Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 80. Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Country, 2020-2034
• Table 81. Brazil Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 82. Brazil Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 83. Brazil Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 84. Mexico Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 85. Mexico Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 86. Mexico Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 87. Rest of Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 88. Rest of Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 89. Rest of Latin America Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 90. Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 91. Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 92. Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 93. Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Country, 2020-2034
• Table 94. South Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 95. South Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 96. South Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 97. Saudi Arabia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 98. Saudi Arabia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 99. Saudi Arabia Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 100. UAE Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 101. UAE Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 102. UAE Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 103. Rest of Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Technology, 2020-2034
• Table 104. Rest of Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Application, 2020-2034
• Table 105. Rest of Middle East & Africa Antisense and RNAi Therapeutics Market Value (US$ Mn), By Route of Administration, 2020-2034

List of Figures

• Figure 1. Global Antisense and RNAi Therapeutics Market Snapshot: Market Value (US$ Mn), 2020-2034
• Figure 2. Opportunity Map
• Figure 3. Opportunity Orbit
• Figure 4. Regional Market Share and BPS Analysis in Antisense and RNAi Therapeutics Market
• Figure 5. Global Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 6. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 7. Global Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 8. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 9. Global Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 10. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 11. Global Antisense and RNAi Therapeutics Market Analysis, By Region, 2020, 2024 and 2034
• Figure 12. Global Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Region
• Figure 13. North America Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 14. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 15. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Antisense RNA, 2020-2034
• Figure 16. North America Antisense and RNAi Therapeutics Market (US$ Mn), by RNA Interference, 2020-2034
• Figure 17. North America Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 18. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 19. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Neurodegenerative Disorders, 2020-2034
• Figure 20. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Genetic Disease, 2020-2034
• Figure 21. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Cancer, 2020-2034
• Figure 22. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Skin Disorders, 2020-2034
• Figure 23. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Respiratory Disorders, 2020-2034
• Figure 24. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Ocular Disorders, 2020-2034
• Figure 25. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Infectious Disease, 2020-2034
• Figure 26. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Cardiometabolic & Renal Disorders, 2020-2034
• Figure 27. North America Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 28. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 29. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Intrathecal Injections, 2020-2034
• Figure 30. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Intravenous Injections, 2020-2034
• Figure 31. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Subcutaneous Injections, 2020-2034
• Figure 32. North America Antisense and RNAi Therapeutics Market (US$ Mn), by Others, 2020-2034
• Figure 33. North America Antisense and RNAi Therapeutics Market Analysis, By Country, 2020, 2024 and 2034
• Figure 34. North America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
• Figure 35. Europe Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 36. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 37. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Antisense RNA, 2020-2034
• Figure 38. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by RNA Interference, 2020-2034
• Figure 39. Europe Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 40. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 41. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Neurodegenerative Disorders, 2020-2034
• Figure 42. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Genetic Disease, 2020-2034
• Figure 43. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Cancer, 2020-2034
• Figure 44. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Skin Disorders, 2020-2034
• Figure 45. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Respiratory Disorders, 2020-2034
• Figure 46. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Ocular Disorders, 2020-2034
• Figure 47. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Infectious Disease, 2020-2034
• Figure 48. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Cardiometabolic & Renal Disorders, 2020-2034
• Figure 49. Europe Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 50. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 51. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Intrathecal Injections, 2020-2034
• Figure 52. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Intravenous Injections, 2020-2034
• Figure 53. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Subcutaneous Injections, 2020-2034
• Figure 54. Europe Antisense and RNAi Therapeutics Market (US$ Mn), by Others, 2020-2034
• Figure 55. Europe Antisense and RNAi Therapeutics Market Analysis, By Country, 2020, 2024 and 2034
• Figure 56. Europe Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
• Figure 57. Asia Pacific Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 58. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 59. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Antisense RNA, 2020-2034
• Figure 60. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by RNA Interference, 2020-2034
• Figure 61. Asia Pacific Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 62. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 63. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Neurodegenerative Disorders, 2020-2034
• Figure 64. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Genetic Disease, 2020-2034
• Figure 65. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Cancer, 2020-2034
• Figure 66. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Skin Disorders, 2020-2034
• Figure 67. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Respiratory Disorders, 2020-2034
• Figure 68. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Ocular Disorders, 2020-2034
• Figure 69. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Infectious Disease, 2020-2034
• Figure 70. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Cardiometabolic & Renal Disorders, 2020-2034
• Figure 71. Asia Pacific Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 72. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 73. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Intrathecal Injections, 2020-2034
• Figure 74. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Intravenous Injections, 2020-2034
• Figure 75. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Subcutaneous Injections, 2020-2034
• Figure 76. Asia Pacific Antisense and RNAi Therapeutics Market (US$ Mn), by Others, 2020-2034
• Figure 77. Asia Pacific Antisense and RNAi Therapeutics Market Analysis, By Country, 2020, 2024 and 2034
• Figure 78. Asia Pacific Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
• Figure 79. Latin America Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 80. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 81. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Antisense RNA, 2020-2034
• Figure 82. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by RNA Interference, 2020-2034
• Figure 83. Latin America Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 84. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 85. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Neurodegenerative Disorders, 2020-2034
• Figure 86. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Genetic Disease, 2020-2034
• Figure 87. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Cancer, 2020-2034
• Figure 88. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Skin Disorders, 2020-2034
• Figure 89. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Respiratory Disorders, 2020-2034
• Figure 90. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Ocular Disorders, 2020-2034
• Figure 91. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Infectious Disease, 2020-2034
• Figure 92. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Cardiometabolic & Renal Disorders, 2020-2034
• Figure 93. Latin America Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 94. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 95. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Intrathecal Injections, 2020-2034
• Figure 96. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Intravenous Injections, 2020-2034
• Figure 97. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Subcutaneous Injections, 2020-2034
• Figure 98. Latin America Antisense and RNAi Therapeutics Market (US$ Mn), by Others, 2020-2034
• Figure 99. Latin America Antisense and RNAi Therapeutics Market Analysis, By Country, 2020, 2024 and 2034
• Figure 100. Latin America Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country
• Figure 101. Middle East & Africa Antisense and RNAi Therapeutics Market Analysis, By Technology, 2020, 2024 and 2034
• Figure 102. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Technology
• Figure 103. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Antisense RNA, 2020-2034
• Figure 104. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by RNA Interference, 2020-2034
• Figure 105. Middle East & Africa Antisense and RNAi Therapeutics Market Analysis, By Application, 2020, 2024 and 2034
• Figure 106. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Application
• Figure 107. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Neurodegenerative Disorders, 2020-2034
• Figure 108. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Genetic Disease, 2020-2034
• Figure 109. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Cancer, 2020-2034
• Figure 110. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Skin Disorders, 2020-2034
• Figure 111. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Respiratory Disorders, 2020-2034
• Figure 112. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Ocular Disorders, 2020-2034
• Figure 113. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Infectious Disease, 2020-2034
• Figure 114. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Cardiometabolic & Renal Disorders, 2020-2034
• Figure 115. Middle East & Africa Antisense and RNAi Therapeutics Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 116. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Route of Administration
• Figure 117. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Intrathecal Injections, 2020-2034
• Figure 118. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Intravenous Injections, 2020-2034
• Figure 119. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Subcutaneous Injections, 2020-2034
• Figure 120. Middle East & Africa Antisense and RNAi Therapeutics Market (US$ Mn), by Others, 2020-2034
• Figure 121. Middle East & Africa Antisense and RNAi Therapeutics Market Analysis, By Country, 2020, 2024 and 2034
• Figure 122. Middle East & Africa Antisense and RNAi Therapeutics Market Attractiveness Analysis, By Country